Reubi J C, Kappeler A, Waser B, Laissue J, Hipkin R W, Schonbrunn A
Institute of Pathology, University of Berne, Switzerland.
Am J Pathol. 1998 Jul;153(1):233-45. doi: 10.1016/S0002-9440(10)65564-2.
Human tumors frequently express somatostatin receptors. However, none of the receptor subtype proteins have been individually visualized in normal or neoplastic human tissues. Here, the distribution of the sst2A receptor was investigated using immunohistochemistry with the specific anti-peptide antibody R2-88 in 47 human tumors. All tumors selected for their abundance of sst2 mRNA and/or strong binding of the sst2-preferring ligand 125I-labeled Tyr3-octreotide were specifically immunostained with R2-88. Conversely, all tumors without somatostatin binding or expressing predominantly other somatostatin receptor subtype mRNAs (sst1 or sst3) were not specifically immunostained by R2-88. Specificity was shown in immunoblots, demonstrating receptor migration as a 70-kd broad band. In immunohistochemical and immunoblotting experiments, the abolition of staining after antibody blockade with antigen peptide was demonstrated. Immunostaining was identified in cryostat and in formalin-fixed, paraffin-embedded sections. Heat-induced epitope retrieval was necessary to visualize sst2A receptors in formalin-fixed sections. Moreover, because of occasional high nonspecific staining, the demonstration of complete abolition of immunostaining by treatment with antigen peptide was a prerequisite for the correct identification of sst2A-positive tumors. The sst2A receptors were clearly located at the membrane of the tumor cells. These results provide the first localization of a somatostatin receptor subtype in human tissues at the cellular level. The sst2A receptor identification and visualization in tumors with simple immunohistochemical methods in formalin-fixed, paraffin-embedded material will open new diagnostic opportunities for pathologists.
人类肿瘤常常表达生长抑素受体。然而,在正常或肿瘤性人类组织中,尚未对任何一种受体亚型蛋白进行单独可视化观察。在此,使用特异性抗肽抗体R2 - 88通过免疫组织化学方法研究了47例人类肿瘤中sst2A受体的分布情况。所有因富含sst2 mRNA和/或对sst2偏好性配体125I标记的酪胺酸3 - 奥曲肽有强结合力而被挑选的肿瘤,均被R2 - 88特异性免疫染色。相反,所有无生长抑素结合或主要表达其他生长抑素受体亚型mRNA(sst1或sst3)的肿瘤,均未被R2 - 88特异性免疫染色。免疫印迹显示了特异性,证明受体迁移为一条70 kDa的宽带。在免疫组织化学和免疫印迹实验中,证实了用抗原肽阻断抗体后染色消失。在低温恒温器切片以及福尔马林固定、石蜡包埋切片中均鉴定出免疫染色。在福尔马林固定切片中,热诱导抗原修复对于可视化sst2A受体是必要的。此外,由于偶尔会出现高非特异性染色,用抗原肽处理后免疫染色完全消失的证明是正确鉴定sst2A阳性肿瘤的先决条件。sst2A受体清晰地定位于肿瘤细胞的膜上。这些结果在细胞水平上首次提供了生长抑素受体亚型在人类组织中的定位。在福尔马林固定、石蜡包埋材料中用简单免疫组织化学方法对肿瘤中的sst2A受体进行鉴定和可视化,将为病理学家开辟新的诊断机会。